Consensus Enfusion, Inc.

Equities

ENFN

US2928121043

Market Closed - Nyse Other stock markets 16:00:02 2024-06-27 EDT			5-day change	1st Jan Change
8.59 ^USD	+2.26%		+5.27%	-11.44%

06-12	Transcript : Enfusion, Inc. Presents at Morgan Stanley US Financials, Payments & CRE Conference 2024, Jun-12-2024 08:00 AM
05-22	Enfusion Insider Sold Shares Worth $325,263, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Enfusion, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1a33358ca30a1e0e51e77d36.1wISfn1ghAOUnYgs-H8_jVP3HIYVolsAvDlk9ayeimk.vmR1BzM1x3f73PpLrAVu-gnHf7R0yyh2-noRreHYzhu7W0IYBxj2UaLqwQ~19ab495fabc5738e835a33c1e48e1ade

Analyst Recommendations on Enfusion, Inc.

Enfusion Insider Sold Shares Worth $325,263, According to a Recent SEC Filing	05-22	MT
BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	03-13	MT
Goldman Sachs Downgrades Enfusion to Sell From Neutral, Trims Price Target to $8 From $9	02-28	MT
JPMorgan Downgrades Enfusion to Underweight From Neutral, Cut Price Target to $9 From $11	01-30	MT
UBS Adjusts Enfusion Price Target to $9.50 From $9, Maintains Neutral Rating	11-08	MT
UBS Initiates Coverage on Enfusion With Neutral Rating, $9 Price Target	11-07	MT
Goldman Sachs Adjusts Enfusion's Price Target to $10 From $11.50, Keeps Neutral Rating	23-08-09	MT
Morgan Stanley Adjusts Enfusion Price Target to $11 From $12, Maintains Overweight Rating	23-08-09	MT
Piper Sandler Adjusts Price Target on Enfusion to $9 From $11, Maintains Neutral Rating	23-05-22	MT
Credit Suisse Trims Enfusion's Price Target to $11 From $14, Keeps Neutral Rating	23-05-10	MT
Piper Sandler Starts Enfusion at Neutral With $11 Price Target	23-04-03	MT
JPMorgan Starts Enfusion at Neutral With $12 Price Target	23-03-15	MT
Goldman Sachs Adjusts Price Target on Enfusion to $11.50 From $9.50, Maintains Neutral Rating	23-03-08	MT
Goldman Sachs Adjusts Price Target on Enfusion to $9.50 From $14, Maintains Neutral Rating	23-01-26	MT
BofA Downgrades Enfusion to Underperform From Neutral, Trims Price Target to $10 From $15	23-01-04	MT
Morgan Stanley Upgrades Enfusion to Overweight From Equalweight, Adjusts Price Target to $12 From $13	23-01-03	MT
Goldman Sachs Adjusts Price Target on Enfusion to $14 From $13, Maintains Neutral Rating	22-11-11	MT
BofA Securities Downgrades Enfusion to Neutral From Buy, Adjusts Price Target to $15 From $17	22-10-03	MT
Goldman Sachs Adjusts Enfusion's Price Target to $13 From $12, Maintains Neutral Rating	22-08-10	MT
Morgan Stanley Raises Enfusion's Price Target to $13 From $8, Maintains Equalweight Rating	22-08-10	MT
Goldman Sachs Lowers Enfusion's Price Target to $12 From $14, Neutral Rating Kept	22-07-14	MT
Piper Sandler Adjusts Enfusion's Price Target to $12 from $15, Keeps Overweight Rating	22-07-06	MT
Credit Suisse Lowers Neutral-Rated Enfusion's Price Target to $13 from $16 Given Recent Market Volatility, Multiple Compression Across Sector	22-05-16	MT
Credit Suisse Adjusts Enfusion's Price Target to $16 from $20, Keeps Neutral Rating	22-05-13	MT
Morgan Stanley Lowers Enfusion's Price Target to $8 From $18, Maintains Equalweight Rating	22-05-13	MT